EBS
Price
$8.86
Change
+$0.04 (+0.45%)
Updated
Aug 15, 04:59 PM (EDT)
Capitalization
470.56M
82 days until earnings call
VTRS
Price
$10.62
Change
-$0.08 (-0.75%)
Updated
Aug 15, 04:59 PM (EDT)
Capitalization
12.46B
87 days until earnings call
Interact to see
Advertisement

EBS vs VTRS

Header iconEBS vs VTRS Comparison
Open Charts EBS vs VTRSBanner chart's image
Emergent Biosolutions
Price$8.86
Change+$0.04 (+0.45%)
Volume$5.49K
Capitalization470.56M
Viatris
Price$10.62
Change-$0.08 (-0.75%)
Volume$113.24K
Capitalization12.46B
EBS vs VTRS Comparison Chart in %
Loading...
EBS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VTRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EBS vs. VTRS commentary
Aug 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EBS is a Hold and VTRS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 16, 2025
Stock price -- (EBS: $8.82 vs. VTRS: $10.69)
Brand notoriety: EBS and VTRS are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: EBS: 59% vs. VTRS: 122%
Market capitalization -- EBS: $470.56M vs. VTRS: $12.46B
EBS [@Pharmaceuticals: Generic] is valued at $470.56M. VTRS’s [@Pharmaceuticals: Generic] market capitalization is $12.46B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.83B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.72B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EBS’s FA Score shows that 0 FA rating(s) are green whileVTRS’s FA Score has 2 green FA rating(s).

  • EBS’s FA Score: 0 green, 5 red.
  • VTRS’s FA Score: 2 green, 3 red.
According to our system of comparison, VTRS is a better buy in the long-term than EBS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EBS’s TA Score shows that 6 TA indicator(s) are bullish while VTRS’s TA Score has 5 bullish TA indicator(s).

  • EBS’s TA Score: 6 bullish, 4 bearish.
  • VTRS’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, EBS is a better buy in the short-term than VTRS.

Price Growth

EBS (@Pharmaceuticals: Generic) experienced а +7.04% price change this week, while VTRS (@Pharmaceuticals: Generic) price change was +13.84% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +6.26%. For the same industry, the average monthly price growth was +68.76%, and the average quarterly price growth was +80.82%.

Reported Earning Dates

EBS is expected to report earnings on Nov 05, 2025.

VTRS is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+6.26% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VTRS($12.5B) has a higher market cap than EBS($471M). VTRS has higher P/E ratio than EBS: VTRS (236.20) vs EBS (3.37). EBS YTD gains are higher at: -7.741 vs. VTRS (-11.810). EBS has higher annual earnings (EBITDA): 105M vs. VTRS (-530.8M). VTRS has more cash in the bank: 1B vs. EBS (149M). EBS has less debt than VTRS: EBS (666M) vs VTRS (14.5B). VTRS has higher revenues than EBS: VTRS (14.3B) vs EBS (930M).
EBSVTRSEBS / VTRS
Capitalization471M12.5B4%
EBITDA105M-530.8M-20%
Gain YTD-7.741-11.81066%
P/E Ratio3.37236.201%
Revenue930M14.3B7%
Total Cash149M1B15%
Total Debt666M14.5B5%
FUNDAMENTALS RATINGS
EBS vs VTRS: Fundamental Ratings
EBS
VTRS
OUTLOOK RATING
1..100
7325
VALUATION
overvalued / fair valued / undervalued
1..100
54
Fair valued
12
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9696
PRICE GROWTH RATING
1..100
4047
P/E GROWTH RATING
1..100
481
SEASONALITY SCORE
1..100
9085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VTRS's Valuation (12) in the null industry is somewhat better than the same rating for EBS (54) in the Biotechnology industry. This means that VTRS’s stock grew somewhat faster than EBS’s over the last 12 months.

VTRS's Profit vs Risk Rating (100) in the null industry is in the same range as EBS (100) in the Biotechnology industry. This means that VTRS’s stock grew similarly to EBS’s over the last 12 months.

VTRS's SMR Rating (96) in the null industry is in the same range as EBS (96) in the Biotechnology industry. This means that VTRS’s stock grew similarly to EBS’s over the last 12 months.

EBS's Price Growth Rating (40) in the Biotechnology industry is in the same range as VTRS (47) in the null industry. This means that EBS’s stock grew similarly to VTRS’s over the last 12 months.

VTRS's P/E Growth Rating (1) in the null industry is somewhat better than the same rating for EBS (48) in the Biotechnology industry. This means that VTRS’s stock grew somewhat faster than EBS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EBSVTRS
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
67%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
56%
Momentum
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
59%
MACD
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
62%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
64%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
62%
Advances
ODDS (%)
Bullish Trend 8 days ago
76%
Bullish Trend 2 days ago
67%
Declines
ODDS (%)
Bearish Trend 15 days ago
88%
Bearish Trend 16 days ago
66%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
64%
Aroon
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
53%
View a ticker or compare two or three
Interact to see
Advertisement
EBS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VTRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FDG115.350.03
+0.02%
American Century Foc Dynmc Gr ETF
LOPP31.20N/A
N/A
Gabelli Love Our Planet & People ETF
BSCU16.87-0.03
-0.18%
Invesco BulletShares 2030 Corp Bd ETF
KEAT27.93-0.06
-0.21%
Keating Active ETF
EDGI26.73-0.10
-0.38%
3EDGE Dynamic International Equity ETF

EBS and

Correlation & Price change

A.I.dvisor indicates that over the last year, EBS has been loosely correlated with SIGA. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if EBS jumps, then SIGA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EBS
1D Price
Change %
EBS100%
+0.34%
SIGA - EBS
42%
Loosely correlated
-2.28%
HROW - EBS
41%
Loosely correlated
+9.62%
AMRX - EBS
41%
Loosely correlated
-0.11%
VTRS - EBS
39%
Loosely correlated
+2.69%
ELAN - EBS
38%
Loosely correlated
+1.07%
More

VTRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, VTRS has been loosely correlated with ELAN. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if VTRS jumps, then ELAN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VTRS
1D Price
Change %
VTRS100%
+2.69%
ELAN - VTRS
54%
Loosely correlated
+1.07%
ZTS - VTRS
47%
Loosely correlated
+0.41%
AMRX - VTRS
47%
Loosely correlated
-0.11%
EBS - VTRS
44%
Loosely correlated
+0.34%
PAHC - VTRS
40%
Loosely correlated
-1.26%
More